A Kanata manufacturer says it plans to invest $1.5-million in new technology to ramp up production of materials used in laboratory tests for COVID-19 and other infectious diseases.
Evik Diagnostic Innovations recently received a $500,000 funding boost from the provincial government. The company says it will put the cash from the Ontario Together Fund toward its plans to increase production of assay reagents, freeze-dried pellets used in diagnostic equipment that detects and analyzes symptoms of diseases such as COVID-19, HIV and anthrax.
The pellets also allow medical device manufacturers to store and ship their devices to remote locations at the proper temperature.
OBJ360 (Sponsored)
uOttawa’s Kanata North campus marks 5 years in Canada’s largest tech park
Whether companies are looking to expand R&D activities, grow their teams, or capitalize on funding opportunities, uOttawa has been there to help.
Wonder and amazement is what you’ll discover at these Ottawa museums
This summer, embark on a journey where curiosity knows no bounds by stepping into the world of innovation and wonder at these Ottawa Museums.
The company says demand for reagent pellets has surged during the pandemic. It plans to build an automated assembly line that will speed up the production of reagent pellets and will also purchase robotic arms, set up robotic stations and build an artificial intelligence-driven assembly station.
“To be competitive and resilient in times of pandemic, companies like us must find ways to be innovative and collaborative,” Evik Diagnostic CEO Vladimir Evtodienko said in a statement.
